Alnylam Pharmaceuticals, Inc.

Ladies and gentlemen, thank you for standing by. And welcome to the Alnylam Pharmaceuticals conference call to discuss fourth quarter and full year 2020 financial results. There will be a question and answer session to follow. Please be advised that this call is being taped at the company's request. I would now like to turn the call over to the company.

Good morning. I'm Christine Lindenboom, Senior Vice President of Investor Relations and Corporate Communications at El Nilem. With me today on the phone are John Merriganori, Chief Executive Officer, Tolga Tangular, Chief Commercial Officer, Akshay Vaishnav, President of R&D, Jeff Fulton, Chief Financial Officer, and Yvonne Greenstreet, President and Chief Operating Officer. In addition, Andy Wirth, Senior Vice President, Head of the U.S. Business, is on the line and available for Q&A. For those of you participating via conference call, the accompanying slides can be accessed by going to the events section of the investor page of our website, investors.elnilam.com slash events. During today's call, as outlined in slide two, John will provide some introductory remarks and provide general context. Togo will provide an update on our global commercial progress. Akshay will review recent clinical and preclinical updates. Jeff will review our financials. And Yvonne will provide a brief summary of upcoming milestones before opening the call to your questions. I would like to remind you that this call will contain remarks concerning L9M's future expectations, plans, and prospects, which constitute forward-looking statements for the purposes of the Safe Harbor provision under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in our most recently quarterly report on file of the SEC. In addition, any forward-looking statements represent our views only of the date of this recording and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update such statements. With that, I'd like to turn the call over to John. John?

Thanks, Christine, and thank you, everyone, for joining the call today. Despite the challenges we all faced in 2020 with the COVID-19 pandemic, Al Milam had one of its strongest years ever as a successful global commercial organization with a highly productive R&D platform. We delivered on our commercial expansion, growing top-line product revenues by over 100%, driven by strong continued execution for Ampatro and Givlari. We continue to advance the pipeline, which includes programs across both rare and common disease populations. And we remain focused on financial discipline to help us reach our goal of achieving a self-sustainable financial profile. Underscoring the success of 2020, We started the year with two products, six approvals, and access in 14 countries. We then ended 2020 with four products, 15 approvals, and access in 41 countries. This includes the approvals of Oxlumo in the EU and the US, and together with our partners at Novartis, Lectio in the EU. We are very proud to have ended 2020 exceeding our Al Milam 2020 goals that we boldly set forth back in 2015. We're now excited to have announced our new five-year strategy and goals with Alnylam P to the fifth by 25. Alnylam P to the fifth by 25 is aimed at fulfilling Alnylam's aspirations and potential of becoming one of the most successful biotech companies ever with transformative medicines in both rare and common diseases for patients around the world supported by additional growth through LIFL expansion, a robust and high-yielding pipeline of first and or best-in-class product candidates from our organic product engine, an exceptional financial performance with over 40% revenue CAGR through year-end 2025, and sustainable profitability achieved within the period. Without a doubt, this is an exciting new chapter for El Nile. Akshay will review our recent R&D progress in just a moment, but an important highlight in the recent period is the positive pipeline results from our Heli-OSA phase 3 study of futriceran. Importantly, we believe that futriceran can significantly expand our opportunity in HATTR amyloidosis with polyneuropathy, positioning L-myelin with continued growth in our ATTR franchise even before our expected expansion in the wild-type ATTR cardiomyopathy setting, assuming favorable clinical results and approvals. Now, for a review of our commercial and medical affairs progress, it's my pleasure to welcome Tolga Tanguilar to his first Alnylam earnings call. Tolga joined Alnylam recently as our chief commercial officer, following roles at Alexion and Pfizer in both rare and common disease franchises, and we're excited about the future of our global commercial efforts under his leadership. With that, let me turn the call over to Tolga. Tolga?